IP Library › Granted Patent US 12,371,485
Granted Patent B2
US 12,371,485 · App. 16/717,064 · Granted Jul 29, 2025

Antigen-binding molecule inducing immune response to target antigen

Inventors: Tomoyuki Igawa (Shizuoka, JP); Atsuhiko Maeda (Shizuoka, JP); Kenta Haraya (Shizuoka, JP); Tatsuhiko Tachibana (Shizuoka, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha
C07K16/28C07K16/283A61K2039/505C07K2317/52C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,485
App. No.
16/717,064
Granted
Jul 29, 2025
Kind
B2
Abstract

The present inventors have discovered that in living organisms that have received an antigen-binding molecule containing an antigen-binding domain whose binding activity to an antigen changes depending on ion concentration conditions and containing an FcRn-binding domain having FcRn-binding activity in a neutral pH range, immune responses to the antigen are induced. Furthermore, the present inventors have discovered that in living organisms that have received an antigen-binding molecule containing an antigen-binding domain whose binding activity to an antigen changes depending on ion concentration conditions and containing an FcRn-binding domain having FcRn-binding activity in a neutral pH range, immune responses to the antigen are induced, and also the antigen-binding molecule has cytotoxicity or antiproliferative action against cancer cells, foreign biological species, or such that express the antigen to which the antigen-binding molecule binds.

Claims (267)

1. A method of producing a pharmaceutical composition that induces humoral immunity to a target antigen, the method comprising:

identifying the amino acid sequence of a first antigen-binding molecule comprising

(i) an antigen-binding domain comprising an antibody heavy chain variable region (VH) and an antibody light chain variable region (VL), wherein the antigen-binding domain binds to the target antigen with an antigen-binding activity that is higher at pH 7.4 than at pH 5.8, and the VL comprises a histidine at one or more of Kabat numbering positions 24, 27, 28, 31, 32, 34, 50, 51, 52, 53, 54, 55, 56, 89, 90, 91, 92, 93, 94, and 95A, and

(ii) a first FcRn-binding domain;

generating a DNA encoding a second antigen-binding molecule comprising the antigen-binding domain and a non-native human IgG1 Fc region comprising a second FcRn-binding domain, wherein the amino acid sequence of the second FcRn-binding domain differs from the amino acid sequence of the first FcRn-binding domain by substitution at one or more positions, wherein at least one of the substitutions is a set of one or more substitutions that matches the set of substitutions present in any one of the variants F10, F12, F14, F32, F34, F36, F38, F40, F47, F49, F50, F53, F54, F58, F59, F61, F69, F71, F73, F78, F80, F82, F84, F86, F88, F90, F92, F93, F95, F101, F103 to F108, F111, F113 to F116 listed in Tables 5-1 to 5-3, wherein all position numbers in Tables 5-1 to 5-3 are according to EU numbering, and wherein the second FcRn-binding domain's binding to a human FcRn receptor at pH 7.4 is greater than the binding of the first FcRn-binding domain to a human FcRn receptor at the same pH;

expressing the DNA, thereby producing the second antigen-binding molecule;

collecting the second antigen-binding molecule; and

producing a pharmaceutical composition comprising the second antigen-binding molecule, wherein the pharmaceutical composition induces humoral immunity to the target antigen.

2. The method of claim 1 , wherein the second antigen-binding molecule binds to and neutralizes the target antigen.

3. The method of claim 1 , wherein the second antigen-binding molecule has cytotoxic activity against a cell expressing the target antigen.

4. The method of claim 1 , wherein the non-native human IgG1 Fc region differs from a native human IgG1 Fc region at one or more positions, including one or more of the following EU numbering positions: 239, 252, 257, 286, 307, 308, 428, and 434.

5. The method of claim 1 , wherein one or more of the following EU numbering positions in the non-native human IgG1 Fc region is occupied by the indicated amino acid:

Ala at position 257;

Pro at position 308;

Leu at position 428;

Tyr at position 434.

6. The method of claim 1 , wherein the non-native human IgG1 Fc region's binding to a human Fcγ receptor is greater than a native human IgG1 Fc region's binding to the human Fcγ receptor, wherein the native human IgG1 Fc region comprises a fucose-containing sugar chain bound at EU numbering position 297.

7. The method of claim 6 , wherein the human Fcγ receptor is FcγRIa, FcγRIIa(R), FcγRIIa(H), FcγRIIb, FcγRIIIa(V), or FcγRIIIa(F).

8. The method of claim 1 , wherein the non-native human IgG1 Fc region differs from a native human IgG1 Fc region at one or more positions, including one or more of the following EU numbering positions: 221, 222, 223, 224, 225, 227, 228, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245, 246, 247, 249, 250, 251, 254, 255, 256, 258, 260, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 278, 279, 280, 281, 282, 283, 284, 285, 286, 288, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 311, 313, 315, 317, 318, 320, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 339, 376, 377, 378, 379, 380, 382, 385, 392, 396, 421, 427, 428, 429, 434, 436, 440.

9. The method of claim 6 , wherein one or more of the following EU numbering positions in the non-native human IgG1 Fc region is occupied by the indicated amino acid:

either Lys or Tyr at position 221;

any one of Phe, Trp, Glu, and Tyr at position 222;

any one of Phe, Trp, Glu, and Lys at position 223;

any one of Phe, Trp, Glu, and Tyr at position 224;

any one of Glu, Lys, and Trp at position 225;

any one of Glu, Gly, Lys, and Tyr at position 227;

any one of Glu, Gly, Lys, and Tyr at position 228;

any one of Ala, Glu, Gly, and Tyr at position 230;

any one of Glu, Gly, Lys, Pro, and Tyr at position 231;

any one of Glu, Gly, Lys, and Tyr at position 232;

any one of Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 233;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 234;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 235;

any one of Ala, Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 236;

any one of Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 237;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 238;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Thr, Val, Trp, and Tyr at position 239;

any one of Ala, Ile, Met, and Thr at position 240;

any one of Asp, Glu, Leu, Arg, Trp, and Tyr at position 241;

any one of Leu, Glu, Leu, Gln, Arg, Trp, and Tyr at position 243;

His at position 244;

Ala at position 245;

any one of Asp, Glu, His, and Tyr at position 246;

any one of Ala, Phe, Gly, His, Ile, Leu, Met, Thr, Val, and Tyr at position 247;

any one of Glu, His, Gln, and Tyr at position 249;

either Glu or Gln at position 250;

Phe at position 251;

any one of Phe, Met, and Tyr at position 254;

any one of Glu, Leu, and Tyr at position 255;

any one of Ala, Met, and Pro at position 256;

any one of Asp, Glu, His, Ser, and Tyr at position 258;

any one of Asp, Glu, His, and Tyr at position 260;

any one of Ala, Glu, Phe, Ile, and Thr at position 262;

any one of Ala, Ile, Met, and Thr at position 263;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Trp, and Tyr at position 264;

any one of Ala, Leu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Val, Trp, and Tyr at position 265;

any one of Ala, Ile, Met, and Thr at position 266;

any one of Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Thr, Val, Trp, and Tyr at position 267;

any one of Asp, Glu, Phe, Gly, Ile, Lys, Leu, Met, Pro, Gln, Arg, Thr, Val, and Trp at position 268;

any one of Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 269;

any one of Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Gln, Arg, Ser, Thr, Trp, and Tyr at position 270;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 271;

any one of Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 272;

either Phe or Ile at position 273;

any one of Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 274;

either Leu or Trp at position 275;

any one of Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 276;

any one of Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, and Trp at position 278;

Ala at position 279;

any one of Ala, Gly, His, Lys, Leu, Pro, Gln, Trp, and Tyr at position 280;

any one of Asp, Lys, Pro, and Tyr at position 281;

any one of Glu, Gly, Lys, Pro, and Tyr at position 282;

any one of Ala, Gly, His, Ile, Lys, Leu, Met, Pro, Arg, and Tyr at position 283;

any one of Asp, Glu, Leu, Asn, Thr, and Tyr at position 284;

any one of Asp, Glu, Lys, Gln, Trp, and Tyr at position 285;

any one of Glu, Gly, Pro, and Tyr at position 286;

any one of Asn, Asp, Glu, and Tyr at position 288;

any one of Asp, Gly, His, Leu, Asn, Ser, Thr, Trp, and Tyr at position 290;

any one of Asp, Glu, Gly, His, Ile, Gln, and Thr at position 291;

any one of Ala, Asp, Glu, Pro, Thr, and Tyr at position 292;

any one of Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 293;

any one of Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 294;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 295;

any one of Ala, Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, and Val at position 296;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 297;

any one of Ala, Asp, Glu, Phe, His, Ile, Lys, Met, Asn, Gln, Arg, Thr, Val, Trp, and Tyr at position 298;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Val, Trp, and Tyr at position 299;

any one of Ala, Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, and Trp at position 300;

any one of Asp, Glu, His, and Tyr at position 301;

Ile at position 302;

any one of Asp, Gly, and Tyr at position 303;

any one of Asp, His, Leu, Asn, and Thr at position 304;

any one of Glu, Ile, Thr, and Tyr at position 305;

any one of Ala, Asp, Asn, Thr, Val, and Tyr at position 311;

Phe at position 313;

Leu at position 315;

either Glu or Gln at position 317;

any one of His, Leu, Asn, Pro, Gln, Arg, Thr, Val, and Tyr at position 318;

any one of Asp, Phe, Gly, His, Ile, Leu, Asn, Pro, Ser, Thr, Val, Trp, and Tyr at position 320;

any one of Ala, Asp, Phe, Gly, His, Ile, Pro, Ser, Thr, Val, Trp, and Tyr at position 322;

Ile at position 323;

any one of Asp, Phe, Gly, His, Ile, Leu, Met, Pro, Arg, Thr, Val, Trp, and Tyr at position 324;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 325;

any one of Ala, Asp, Glu, Gly, Ile, Leu, Met, Asn, Pro, Gln, Ser, Thr, Val, Trp, and Tyr at position 326;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Thr, Val, Trp, and Tyr at position 327;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 328;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 329;

any one of Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 330;

any one of Asp, Phe, His, Ile, Leu, Met, Gln, Arg, Thr, Val, Trp, and Tyr at position 331;

any one of Ala, Asp, Glu, Phe, Gly, His, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 332;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Ser, Thr, Val, and Tyr at position 333;

any one of Ala, Glu, Phe, Ile, Leu, Pro, and Thr at position 334;

any one of Asp, Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Val, Trp, and Tyr at position 335;

any one of Glu, Lys, and Tyr at position 336;

any one of Glu, His, and Asn at position 337;

any one of Asp, Phe, Gly, Ile, Lys, Met, Asn, Gln, Arg, Ser, and Thr at position 339;

either Ala or Val at position 376;

either Gly or Lys at position 377;

Asp at position 378;

Asn at position 379;

any one of Ala, Asn, and Ser at position 380;

either Ala or Ile at position 382;

Glu at position 385;

Thr at position 392;

Leu at position 396;

Lys at position 421;

Asn at position 427;

either Phe or Leu at position 428;

Met at position 429;

Trp at position 434;

Ile at position 436;

any one of Gly, His, Ile, Leu, and Tyr at position 440.

10. The method of claim 6 , wherein the percentage of the second antigen-binding molecule that has a fucose-deficient sugar chain bound at EU numbering position 297 in the pharmaceutical composition is higher than the percentage of a naturally-occurring IgG1 that has a fucose-deficient sugar chain bound at EU numbering position 297 in a composition of the naturally-occurring IgG1.

11. The method of claim 6 , wherein the percentage of the second antigen-binding molecule that has a bisecting N-acetylglucosamine sugar chain bound at EU numbering position 297 in the pharmaceutical composition is higher than the percentage of a naturally-occurring IgG1 that has a bisecting N-acetylglucosamine sugar chain bound at EU numbering position 297 in a composition of the naturally-occurring IgG.

12. A method of producing a pharmaceutical composition that induces humoral immunity to a target antigen, the method comprising:

(a) identifying the amino acid sequence of a first antigen-binding molecule comprising a first FcRn-binding domain and an antigen-binding domain comprising a VH and a VL, wherein the antigen-binding domain binds to the target antigen, and the VL comprises a histidine at one or more of Kabat numbering positions 24, 27, 28, 31, 32, 34, 50, 51, 52, 53, 54, 55, 56, 89, 90, 91, 92, 93, 94, and 95A;

(b) testing the antigen-binding domain's antigen-binding activity at a first pH between pH 6.7-10.0 and at a second pH between pH 4.0-6.5, and determining that the antigen-binding activity is greater at the first pH than at the second pH;

(c) generating a DNA encoding a second antigen-binding molecule comprising the antigen-binding domain and a non-native human IgG1 Fc region comprising a second FcRn-binding domain that binds to a human FcRn receptor at pH 7.4, wherein the amino acid sequence of the second FcRn-binding domain differs from the amino acid sequence of the first FcRn-binding domain by substitution at one or more positions, wherein at least one of the substitutions is a set of one or more substitutions that matches the set of substitutions present in any one of variants F10, F12, F14, F25, F32, F34, F36, F38, F40, F47, F49, F50, F53, F54, F58, F59, F61, F69, F71, F73, F78, F80, F82, F84, F86, F88, F90, F92, F93, F95, F101, F103 to F108, F111, F113 to F116 listed in Tables 5-1 to 5-3; wherein all position numbers in Tables 5-1 to 5-3 are according to EU numbering,

(d) culturing cells comprising the DNA, so that the cells express the second antigen-binding molecule;

(e) collecting the second antigen-binding molecule; and

(f) producing a pharmaceutical composition comprising the second antigen-binding molecule, wherein the pharmaceutical composition induces humoral immunity to the target antigen.

13. The method of claim 12 , wherein the second antigen-binding molecule is an antibody.

14. The method of claim 12 , wherein the second antigen-binding molecule binds to and neutralizes the target antigen.

15. The method of claim 12 , wherein the second antigen-binding molecule has cytotoxic activity against a cell expressing the target antigen.

16. The method of claim 12 , wherein the non-native human IgG1 Fc region differs from a native human IgG Fc region at one or more of the following EU numbering positions: 257, 308, 428, 434.

17. The method of claim 12 , wherein one or more of the following EU numbering positions in the non-native human IgG1 Fc region is occupied by the indicated amino acid:

Ala at position 257;

Pro at position 308;

Leu at position 428;

Tyr at position 434.

18. The method of claim 12 , wherein the non-native human IgG1 Fc region's binding to a human Fcγ receptor is greater than a native human IgG Fc region's binding to the human Fcγ receptor, wherein the native human IgG Fc region comprises a fucose-containing sugar chain bound at EU numbering position 297.

19. The method of claim 18 , wherein the human Fcγ receptor is FcγRIa, FcγRIIa(R), FcγRIIa(H), FcγRIIb, FcγRIIIa(V), or FcγRIIIa(F).

20. The method of claim 18 , wherein one or more of the following EU numbering positions in the non-native human IgG1 Fc region is occupied by the indicated amino acid:

either Lys or Tyr at position 221;

any one of Phe, Trp, Glu, and Tyr at position 222;

any one of Phe, Trp, Glu, and Lys at position 223;

any one of Phe, Trp, Glu, and Tyr at position 224;

any one of Glu, Lys, and Trp at position 225;

any one of Glu, Gly, Lys, and Tyr at position 227;

any one of Glu, Gly, Lys, and Tyr at position 228;

any one of Ala, Glu, Gly, and Tyr at position 230;

any one of Glu, Gly, Lys, Pro, and Tyr at position 231;

any one of Glu, Gly, Lys, and Tyr at position 232;

any one of Ala, Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 233;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 234;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 235;

any one of Ala, Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 236;

any one of Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 237;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 238;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Thr, Val, Trp, and Tyr at position 239;

any one of Ala, Ile, Met, and Thr at position 240;

any one of Asp, Glu, Leu, Arg, Trp, and Tyr at position 241;

any one of Leu, Glu, Leu, Gln, Arg, Trp, and Tyr at position 243;

His at position 244;

Ala at position 245;

any one of Asp, Glu, His, and Tyr at position 246;

any one of Ala, Phe, Gly, His, Ile, Leu, Met, Thr, Val, and Tyr at position 247;

any one of Glu, His, Gln, and Tyr at position 249;

either Glu or Gln at position 250;

Phe at position 251;

any one of Phe, Met, and Tyr at position 254;

any one of Glu, Leu, and Tyr at position 255;

any one of Ala, Met, and Pro at position 256;

any one of Asp, Glu, His, Ser, and Tyr at position 258;

any one of Asp, Glu, His, and Tyr at position 260;

any one of Ala, Glu, Phe, Ile, and Thr at position 262;

any one of Ala, Ile, Met, and Thr at position 263;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Trp, and Tyr at position 264;

any one of Ala, Leu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Val, Trp, and Tyr at position 265;

any one of Ala, Ile, Met, and Thr at position 266;

any one of Asp, Glu, Phe, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Thr, Val, Trp, and Tyr at position 267;

any one of Asp, Glu, Phe, Gly, Ile, Lys, Leu, Met, Pro, Gln, Arg, Thr, Val, and Trp at position 268;

any one of Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 269;

any one of Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Gln, Arg, Ser, Thr, Trp, and Tyr at position 270;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 271;

any one of Asp, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 272;

either Phe or Ile at position 273;

any one of Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 274;

either Leu or Trp at position 275;

any one of Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 276;

any one of Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, and Trp at position 278;

Ala at position 279;

any one of Ala, Gly, His, Lys, Leu, Pro, Gln, Trp, and Tyr at position 280;

any one of Asp, Lys, Pro, and Tyr at position 281;

any one of Glu, Gly, Lys, Pro, and Tyr at position 282;

any one of Ala, Gly, His, Ile, Lys, Leu, Met, Pro, Arg, and Tyr at position 283;

any one of Asp, Glu, Leu, Asn, Thr, and Tyr at position 284;

any one of Asp, Glu, Lys, Gln, Trp, and Tyr at position 285;

any one of Glu, Gly, Pro, and Tyr at position 286;

any one of Asn, Asp, Glu, and Tyr at position 288;

any one of Asp, Gly, His, Leu, Asn, Ser, Thr, Trp, and Tyr at position 290;

any one of Asp, Glu, Gly, His, Ile, Gln, and Thr at position 291;

any one of Ala, Asp, Glu, Pro, Thr, and Tyr at position 292;

any one of Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 293;

any one of Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 294;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 295;

any one of Ala, Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, and Val at position 296;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 297;

any one of Ala, Asp, Glu, Phe, His, Ile, Lys, Met, Asn, Gln, Arg, Thr, Val, Trp, and Tyr at position 298;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Val, Trp, and Tyr at position 299;

any one of Ala, Asp, Glu, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, and Trp at position 300;

any one of Asp, Glu, His, and Tyr at position 301;

Ile at position 302;

any one of Asp, Gly, and Tyr at position 303;

any one of Asp, His, Leu, Asn, and Thr at position 304;

any one of Glu, Ile, Thr, and Tyr at position 305;

any one of Ala, Asp, Asn, Thr, Val, and Tyr at position 311;

Phe at position 313;

Leu at position 315;

either Glu or Gln at position 317;

any one of His, Leu, Asn, Pro, Gln, Arg, Thr, Val, and Tyr at position 318;

any one of Asp, Phe, Gly, His, Ile, Leu, Asn, Pro, Ser, Thr, Val, Trp, and Tyr at position 320;

any one of Ala, Asp, Phe, Gly, His, Ile, Pro, Ser, Thr, Val, Trp, and Tyr at position 322;

Ile at position 323;

any one of Asp, Phe, Gly, His, Ile, Leu, Met, Pro, Arg, Thr, Val, Trp, and Tyr at position 324;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 325;

any one of Ala, Asp, Glu, Gly, Ile, Leu, Met, Asn, Pro, Gln, Ser, Thr, Val, Trp, and Tyr at position 326;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Thr, Val, Trp, and Tyr at position 327;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 328;

any one of Asp, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 329;

any one of Cys, Glu, Phe, Gly, His, Ile, Lys, Leu, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, and Tyr at position 330;

any one of Asp, Phe, His, Ile, Leu, Met, Gln, Arg, Thr, Val, Trp, and Tyr at position 331;

any one of Ala, Asp, Glu, Phe, Gly, His, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, and Tyr at position 332;

any one of Ala, Asp, Glu, Phe, Gly, His, Ile, Leu, Met, Pro, Ser, Thr, Val, and Tyr at position 333;

any one of Ala, Glu, Phe, Ile, Leu, Pro, and Thr at position 334;

any one of Asp, Phe, Gly, His, Ile, Leu, Met, Asn, Pro, Arg, Ser, Val, Trp, and Tyr at position 335;

any one of Glu, Lys, and Tyr at position 336;

any one of Glu, His, and Asn at position 337;

any one of Asp, Phe, Gly, Ile, Lys, Met, Asn, Gln, Arg, Ser, and Thr at position 339;

either Ala or Val at position 376;

either Gly or Lys at position 377;

Asp at position 378;

Asn at position 379;

any one of Ala, Asn, and Ser at position 380;

either Ala or Ile at position 382;

Glu at position 385;

Thr at position 392;

Leu at position 396;

Lys at position 421;

Asn at position 427;

either Phe or Leu at position 428;

Met at position 429;

Trp at position 434;

Ile at position 436;

any one of Gly, His, Ile, Leu, and Tyr at position 440.

21. The method of claim 18 , wherein the percentage of the second antigen-binding molecule that has a fucose-deficient sugar chain bound at EU numbering position 297 in the pharmaceutical composition is higher than the percentage of a naturally-occurring IgG that has a fucose-deficient sugar chain bound at EU numbering position 297 in a composition of the naturally-occurring IgG.

22. The method of claim 18 , wherein the percentage of the second antigen-binding molecule that has a bisecting N-acetylglucosamine sugar chain bound at EU numbering position 297 in the pharmaceutical composition is higher than the percentage of a naturally-occurring IgG that has a bisecting N-acetylglucosamine sugar chain bound at EU numbering position 297 in a composition of the naturally-occurring IgG.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: IGAWA, TOMOYUKI; MAEDA, ATSUHIKO; HARAYA, KENTA; TACHIBANA, TATSUHIKO
To: CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 051820/0346 →
Priority Claims (1)
JP 2011-216958 · Sep 30, 2011 · national
Continuity (2)
Division 14347448
Related Publication 20200115447A1 · Apr 16, 2020
References Cited (178)
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6602684B1 · Umana et al. · 2003 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 8568726B2 · Beaumont et al. · 2013 [cited by applicant]
US 9029515B2 · Pons et al. · 2015 [cited by applicant]
US 10011858B2 · Igawa · 2018 [cited by examiner]
US 10556949B2 · Igawa · 2020 [cited by examiner]
US 10618965B2 · Igawa · 2020 [cited by examiner]
US 11124576B2 · Igawa · 2021 [cited by examiner]
US 11142587B2 · Igawa · 2021 [cited by examiner]
US 11168344B2 · Igawa · 2021 [cited by examiner]
US 11718678B2 · Igawa · 2023 [cited by examiner]
US 11827699B2 · Igawa · 2023 [cited by examiner]
US 20060067930A1 · Adams et al. · 2006 [cited by applicant]
US 20060141456A1 · Edwards et al. · 2006 [cited by applicant]
US 20060173170A1 · Chamberlain · 2006 [cited by examiner]
US 20070111281A1 · Sondermann et al. · 2007 [cited by applicant]
US 20070148164A1 · Farrington et al. · 2007 [cited by applicant]
US 20080089892A1 · Allan et al. · 2008 [cited by applicant]
US 20080181887A1 · Dall-Acqua · 2008 [cited by examiner]
US 20090215991A1 · Lazar et al. · 2009 [cited by applicant]
US 20100098730A1 · Lowman · 2010 [cited by examiner]
US 20100330076A1 · Georgiou et al. · 2010 [cited by applicant]
US 20110111406A1 · Igawa · 2011 [cited by examiner]
US 20120009188A1 · Behrens et al. · 2012 [cited by applicant]
US 20130011866A1 · Igawa et al. · 2013 [cited by applicant]
US 20130131319A1 · Igawa et al. · 2013 [cited by applicant]
US 20130303396A1 · Igawa et al. · 2013 [cited by applicant]
US 20140105889A1 · Igawa et al. · 2014 [cited by applicant]
US 20140234340A1 · Igawa et al. · 2014 [cited by applicant]
US 20140255398A1 · Igawa et al. · 2014 [cited by applicant]
US 20140271617A1 · Igawa et al. · 2014 [cited by applicant]
US 20140335089A1 · Igawa et al. · 2014 [cited by applicant]
US 20140363428A1 · Igawa et al. · 2014 [cited by applicant]
US 20150056182A1 · Igawa et al. · 2015 [cited by applicant]
US 20150166654A1 · Igawa et al. · 2015 [cited by applicant]
US 20150353630A1 · Igawa et al. · 2015 [cited by applicant]
US 20160176954A1 · Ruike et al. · 2016 [cited by applicant]
US 20160200807A1 · Ruike et al. · 2016 [cited by applicant]
US 20160229908A1 · Igawa et al. · 2016 [cited by applicant]
CN 1997667 · 2007 [cited by applicant]
CN 101291954 · 2008 [cited by applicant]
CN 101589057 · 2009 [cited by applicant]
CN 101679966 · 2010 [cited by applicant]
CN 102056946 · 2011 [cited by applicant]
CN 102245208 · 2011 [cited by applicant]
EP 2119780A · 2009 [cited by applicant]
EP 2275443 · 2011 [cited by applicant]
EP 2752200A · 2014 [cited by applicant]
JP 2008505174 · 2008 [cited by applicant]
MX 366968 · 2019 [cited by applicant]
RU 2318829 · 2008 [cited by applicant]
WO WO0042072 · 2000 [cited by applicant]
WO WO2004039826 · 2004 [cited by applicant]
WO WO2005110474 · 2005 [cited by applicant]
WO WO2006019447 · 2006 [cited by applicant]
WO WO2006130834 · 2006 [cited by applicant]
WO WO2007031875 · 2007 [cited by applicant]
WO WO2008043822 · 2008 [cited by applicant]
WO WO2009125825 · 2009 [cited by applicant]
WO WO2009125825A1 · 2009 [cited by examiner]
WO WO2009139822 · 2009 [cited by applicant]
WO WO2010045193 · 2010 [cited by applicant]
WO WO2010058860 · 2010 [cited by applicant]
WO WO2010085682 · 2010 [cited by applicant]
WO WO2010088444 · 2010 [cited by applicant]
WO WO2011122011 · 2011 [cited by applicant]
WO WO2011122011A2 · 2011 [cited by examiner]
WO WO2012073992 · 2012 [cited by applicant]
WO WO2016000813 · 2016 [cited by applicant]
Lloyd et al., Protein Engineering, Design & Selection 22:159-168 (Year: 2009). [cited by examiner]
Edwards et al., J Mol Biol. 334(1): 103-118 (Year: 2003). [cited by examiner]
Chalaris et al., “The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer,” Eur J Cell Biol, Jun.-Jul. 2011, 90(6-7):484-494. doi: 10.1016/j.ejcb.2010.10.007. Epub Dec. 8, 2010. PMID: 21145125. [cited by applicant]
Elvin et al., Sequences of Proteins of Immunological Interest, 1991, Table of Contents, p. iv, pp. 661, 662, 671. [cited by applicant]
Ober et al., “Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies,” Int Immunol, Dec. 2001, 13(12):1551-1559. [cited by applicant]
Adams et al., “Monoclonal antibody therapy of cancer,” Nat Biotechnol, Sep. 2005, 23(9):1147-57. [cited by applicant]
Bonvin et al., “De novo isolation of antibodies with pH-dependent binding properties,” mAbs, Mar./Apr. 2015, 7(2):294-302. [cited by applicant]
Borrok et al., “pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling,” J Biol Chem, Feb. 13, 2015, 290(7):4282-90. doi: 10.1074/jbc.M114.603712. Epub Dec. 23, 2014. [cited by applicant]
Bronte et al., “IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases,” J Immunol, May 15, 1995, 154(10):5282-92. [cited by applicant]
Cartron et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene,” Blood, Feb. 1, 2002, 99(3):754-8. [cited by applicant]
Chaparro-Riggers et al., “Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9,” J Biol Chem, Mar. 30, 2012, 287(14):11090-7. doi: 10.1074/jbc.… [cited by applicant]
Chen et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” EMBO J, Jun. 15, 1995, 14(12):2784-94. [cited by applicant]
Clark, “IgG effector mechanisms,” Chem Immunol, 1997, 65:88-110. [cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc Natl Acad Sci USA, Jan. 1998, 95(2):652-6. [cited by applicant]
Clynes et al., “Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets,” Nat Med, Apr. 2000, 6(4):443-6. [cited by applicant]
Dall'Acqua et al., “Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn),” J Biol Chem, Aug. 18, 2006, 281(33):23514-24. Epub Jun. 21, 2006. [cited by applicant]
Dall'Acqua et al., “Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences,” J Immunol, Nov. 1, 2002, 169(9):5171-80. [cited by applicant]
De Felice et al., “Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure,” FASEB J, Jul. 2004, 18(10):1099-101. (dol:10.1096/fj.03-1072fje; PMID 15155566). [cited by applicant]
Deng et al., “Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{ alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys,” Drug Metab Dispos, Apr. 2010, 38(4):600-5. doi: … [cited by applicant]
Devanaboyina et al., “The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics,” mAbs, Nov.-Dec. 2013, 5(6):851-9. doi: 10.4161/mabs.26389. [cited by applicant]
Dufner et al., “Harnessing phage and ribosome display for antibody optimization,” Trends Biotechnol, Nov. 2006, 24(11):523-9. [cited by applicant]
Fukuzawa et al., “Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases,” Sci Reports 7, Apr. 24, 2017, 1080:1-12. [cited by applicant]
Greenwood et al., “Structural motifs involved in human IgG antibody effector functions,” Eur J Immunol, May 1993, 23(5):1098-104. [cited by applicant]
Horton et al., “Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia,” Cancer Res, Oct. 1, 2008, 68(19):8049-57. [cited by applicant]
Igawa et al., “pH-dependent antigen-binding antibodies as a novel therapeutic modality,” Biochim Biophys Acta, Nov. 2014, 1844(11):1943-1950. doi: 10.1016/j.bbapap.2014.08.003. Epub Aug. 12, 2014. [cited by applicant]
Igawa et al., “Engineered monoclonal antibody with novel antigen-sweeping activity in vivo,” PLoS One, May 7, 2013, 8(5):e63236. doi: 10.1371/journal.pone.0063236. Print 2013. [cited by applicant]
Igawa et al., “Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization,” Nat Biotechnol, Nov. 2010, 28(11):1203-7. [cited by applicant]
Igawa et al., “Reduced elimination of IgG antibodies by engineering the variable region,” Protein Eng Des Sel, Feb. 15, 2010, 23(5):385-92. [cited by applicant]
Igawa et al., “Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation,” Immunol Rev, Mar. 2016, 270(1): 132-151. [cited by applicant]
Janeway et al., Chapter 3 “Structure of the Antibody Molecule and Immunoglobulin Genes,” Immunobiology, The Immune System in Health and Disease, 3 [cited by applicant]
Jefferis et al., “Interaction sites on human IgG—Fc for FcγR: current Models,” Immunol Lett, Jun. 2002, 82(1-2):57-65. [cited by applicant]
Kussie et al., “A single engineered amino acid substitution changes antibody fine specificity,” J Immunol, Jan. 1, 1994, 152(1):146-52. [cited by applicant]
Lazar et al., “Engineered antibody Fc variants with enhanced effector function,” Proc Natl Acad Sci USA, Mar. 14, 2006, 103(11):4005-10. [cited by applicant]
Mi et al., “Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments,” J Immunol, Dec. 1, 2008, 181(11):7550-61. [cited by applicant]
Morgan et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding,” Immunology, Oct. 1995, 86(2):319-24. [cited by applicant]
Nimmerjahn et al., “Divergent immunoglobulin g subclass activity through selective Fc receptor binding,” Science, Dec. 2, 2005, 310(5753):1510-2. [cited by applicant]
Ober et al., “Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level,” Proc Natl Acad Sci USA, Jul. 27, 2004, 101(30):11076-81. Epub Jul. 16, 2004. [cited by applicant]
Oettgen et al., Chapter 6 “The History of Cancer Immunotherapy,” Biological Therapy of Cancer, 1991, pp. 87-119. [cited by applicant]
Park et al., “The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity,” Cancer Cell, Aug. 17, 2010, 18(2):160-70. [cited by applicant]
Pavlou et al., “The therapeutic antibodies market to 2008,” Eur J Pharm Biopharm, Apr. 2005, 59(3):389-396. [cited by applicant]
Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” Int Immunol, Dec. 2006, 18(12):1759-6… [cited by applicant]
Raghavan et al., “Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants,” Biochemistry, Nov. 14, 1995, 34(45):14649-57. [cited by applicant]
Reichert et al., “Monoclonal antibody successes in the clinic,” Nat Biotechnol, Sep. 2005, 23(9):1073-78. [cited by applicant]
Reverberi et al., “Factors affecting the antigen-antibody reaction,” Blood Transfus, Nov. 2007, 5(4):227-40. doi: 10.2450/2007.0047-07. [cited by applicant]
Roitt et al., “Antibody Structure and Function,” Immunology, Moscow, Mir, 2000, pp. 110-111 (in Russian, with what is believed to be a published English equivalent of those pages). [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci USA, Mar. 1982, 79(6):1979-83. [cited by applicant]
Schuster et al., “Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF,” J Biol Chem, Mar. 14, 2003, 278(11):9528-35. [cited by applicant]
Seda et al., “B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells,” Eur J Haematol, Mar. 2015, 94(3):193-205. doi: 10.1111/ejh.12427. Epub Sep. 13, 2014. [cited by applicant]
Shinkawa et al., “The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cyt… [cited by applicant]
Singer et al., “The Genetic Molecules,” Genes & Genomes, Moscow, Mir, 1998, vol. 1, pp. 63-64 (in Russian, with what is believed to be a published English equivalent of those pages). [cited by applicant]
Suzuki et al., “Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion pro… [cited by applicant]
Tanabe et al., “Characterization of the Monoclonal Antibodies against Human Protein C Specific for Calcium Ion-induced Conformers,” Japanese Journal of Thrombosis and Hemostasis, 1992, 3(1):29-35. [cited by applicant]
Tanzi et al., “Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective,” Cell, Feb. 2005, 120(4):545-55. (doi:10.1016/j.cell.2005.02.008; PMID 15734686). [cited by applicant]
Taylor et al., “Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy,” Clin Cancer Res, Sep. 1, 2007, 13(17):5133-43. [cited by applicant]
Tsuji et al., “Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity,” J Immunol, Jan. 15, 2011, 186(2):1218-27. Epub Dec. 13… [cited by applicant]
Vaccaro et al., “Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels,” Nat Biotechnol, Oct. 2005, 23(10):1283-8. Epub Sep. 25, 2005. [cited by applicant]
Wang et al., “Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences,” Drug Metab Dispos, Sep. 2011, 39(9):1469-77. doi: 10.1124/dmd.111.039453. Epub May 24, … [cited by applicant]
Wolf et al., “BiTEs: bispecific antibody constructs with unique anti-tumor activity,” Drug Discov Today, Sep. 15, 2005, 10(18):1237-44. [cited by applicant]
Wu et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,” J Mol Biol, Nov. 19, 1999, 294(1):151-62. [cited by applicant]
Yeung et al., “Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates,” J Immunol, Jun. 15, 2009, 182(12):7663-71. doi: 10.4049/jimmunol.0804182. [cited by applicant]
Yu et al., “Interaction between bevacizumab and murine VEGF-A: a reassessment,” Invest Ophthalmol Vis Sci, Feb. 2008, 49(2):522-7. [cited by applicant]
Zalevsky et al., “The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates,” Blood, Apr. 16, 2009, 113(16):3735-43. Epub Dec. 24, 2008. [cited by applicant]
Zalevsky et al., “Enhanced antibody half-life improves in vivo activity,” Nat Biotechnol, Feb. 2010, 28(2):157-9. [cited by applicant]
Zatloukal et al., “Somatic gene therapy for cancer: the utility of transferrinfection in generating ‘tumor vaccines’,” Gene, Dec. 15, 1993, 135(1-2):199-207. [cited by applicant]
International Search Report for App. Ser. No. PCT/JP2012/075403, mailed Nov. 27, 2012, 4 pages. [cited by applicant]
International Preliminary Report on Patentability for App. Ser. No. PCT/JP2012/075403, dated Apr. 1, 2014, 9 pages. [cited by applicant]
USPTO Restriction Requirement in U.S. Appl. No. 14/347,034, dated Dec. 18, 2014, 9 pages. [cited by applicant]
Fish & Richardson P.C., Reply to Restriction Requirement dated Dec. 18, 2014 in U.S. Appl. No. 14/347,034, filed Mar. 18, 2015, 2 pages. [cited by applicant]
USPTO Non-Final Office Action in U.S. Appl. No. 14/347,034, dated Apr. 16, 2015, 9 pages. [cited by applicant]
USPTO Interview Summary in U.S. Appl. No. 14/347,034, dated Aug. 17, 2015, 3 pages. [cited by applicant]
Fish & Richardson P.C., Reply to Non-Final Office Action dated Apr. 16, 2015 in U.S. Appl. No. 14/347,034, filed Sep. 16, 2015, 28 pages. [cited by applicant]
USPTO Final Office Action in U.S. Appl. No. 14/347,034, dated Oct. 16, 2015, 5 pages. [cited by applicant]
Fish & Richardson P.C., Reply to Final Office Action dated Oct. 16, 2015 in U.S. Appl. No. 14/347,034, filed Jan. 13, 2016, 28 pages. [cited by applicant]
USPTO Notice of Allowance in U.S. Appl. No. 14/347,034, dated Feb. 17, 2016, 6 pages. [cited by applicant]
USPTO Notice of Allowance in U.S. Appl. No. 14/347,034, dated Jun. 3, 2016, 5 pages. [cited by applicant]
USPTO Notice of Allowance in U.S. Appl. No. 14/347,034, dated Sep. 22, 2016, 9 pages. [cited by applicant]
USPTO Non-Final Office Action in U.S. Appl. No. 14/347,034, dated May 25, 2017, 16 pages. [cited by applicant]
USPTO Non-Final Office Action in U.S. Appl. No. 14/347,034, dated Jan. 8, 2018, 15 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/230,904, dated May 25, 2017, 9 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/230,904, dated Jan. 8, 2018, 16 pages. [cited by applicant]
USPTO Restriction Requirement in U.S. Appl. No. 14/347,187, dated Jan. 26, 2017, 9 pages. [cited by applicant]
USPTO Non-Final Office Action in U.S. Appl. No. 14/347,187, dated Jun. 14, 2017, 23 pages. [cited by applicant]
Fish & Richardson P.C., Reply to Non-Final Office Action dated Jun. 14, 2017, in U.S. Appl. No. 14/347,187, filed Oct. 16, 2017, 36 pages. [cited by applicant]
USPTO Final Office Action in U.S. Appl. No. 14/347,187, dated Jan. 19, 2018, 24 pages. [cited by applicant]
USPTO Applicant-Initiated Interview Summary in U.S. Appl. No. 14/347,187, dated Jul. 10, 2018, 3 pages. [cited by applicant]
USPTO Non-Final Office Action in U.S. Appl. No. 14/347,187, dated Sep. 4, 2018, 22 pages. [cited by applicant]
USPTO Notice of Allowance in U.S. Appl. No. 14/347,187, dated Jan. 7, 2019, 13 pages. [cited by applicant]
USPTO Non-Final Office Action in U.S. Appl. No. 16/028,140, dated Jul. 9, 2019, 95 pages. [cited by applicant]
Kim et al., “Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model,” Clin Immunol, Feb. 2007, 122(2):146-155. doi: 10.1016… [cited by applicant]
Fish & Richardson P.C., Reply to Restriction Requirement in U.S. Appl. No. 14/347,448, filed Mar. 21, 2016, 13 pages. [cited by applicant]
Fish & Richardson P.C., Amendment and Reply to Action of May 26, 2016 in U.S. Appl. No. 14/347,448, filed Nov. 28, 2016, 27 pages. [cited by applicant]
Fish & Richardson P.C., Amendment and Reply to Action of Feb. 21, 2017 in U.S. Appl. No. 14/347,448, filed Aug. 18, 2017, 46 pages. [cited by applicant]
Fish & Richardson P.C., Reply to Restriction Requirement in U.S. Appl. No. 14/347,448, filed Feb. 22, 2018, 3 pages. [cited by applicant]
Fish & Richardson P.C., Amendment and Reply to Non-Final Action of Mar. 9, 2018 in U.S. Appl. No. 14/347,448, filed Sep. 5, 2018, 41 pages. [cited by applicant]
Fish & Richardson P.C., Amendment and Reply to Final Office Action of Nov. 13, 2018 in U.S. Appl. No. 14/347,448, filed May 10, 2019, 19 pages. [cited by applicant]
USPTO Restriction Requirement in U.S. Appl. No. 14/347,448, dated Dec. 21, 2015, 8 pages. [cited by applicant]
USPTO Non-Final Office Action in U.S. Appl. No. 14/347,448, dated May 26, 2016, 54 pages. [cited by applicant]
USPTO Final Office Action in U.S. Appl. No. 14/347,448, dated Feb. 21, 2017, 45 pages. [cited by applicant]
USPTO Interview Summary in U.S. Appl. No. 14/347,448, dated Aug. 16, 2017, 4 pages. [cited by applicant]
USPTO Restriction Requirement in U.S. Appl. No. 14/347,448, dated Nov. 24, 2017, 13 pages. [cited by applicant]
USPTO Non-Final Office Action in U.S. Appl. No. 14/347,448, dated Mar. 9, 2018, 32 pages. [cited by applicant]
USPTO Final Office Action in U.S. Appl. No. 14/347,448, dated Nov. 13, 2018, 29 pages. [cited by applicant]
USPTO Notice of Allowance in U.S. Appl. No. 14/347,448, dated Sep. 26, 2019, 12 pages. [cited by applicant]
Min et al., “Anti-CD20 Monoclonal Antibody RTX Enhances Radiosensitivity of Lymphoma Cells,” Journal of Experimental Hematology, 2010, 18(3):660-665 (with English translation). [cited by applicant]
Qiu, “scFv antibodies binding to FcRn pH-dependently enable to prolong serum half-life of therapeutic protein,” Ph.D. Dissertation Submitted to School of Pharmacy, Shanghai Jiao Tong University, May 2016 (with English t… [cited by applicant]
Vaughn et al., “Structural basis of pH-dependent antibody binding by the neonatal Fc receptor,” Structure, Jan. 15, 1998;6(1):63-73. [cited by applicant]
Wang et al., “Advance on Production and Application of Humanized Antibody,” Letters in Biotechnology, 2007, 18(4):683-687 (with English translation). [cited by applicant]
Yang et al., “Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn,” mAbs, Oct. 2017, 9(7):1105-1117. doi: 10.1080/19420862.2017.1359455. Epub Aug. 8, 201… [cited by applicant]